Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Bazedoxifene
Introduction
Bazedoxifene is a selective estrogen receptor modulator (SERM), developed by Wyeth Pharmaceuticals, undergoing clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. It is currently in the early phases of review by the United States’ Food and Drug Administration. When approved, bazedoxifene is to be sold by Wyeth under the tradename Viviantâ„¢. Bazedoxifene’s combination with conjugated estrogens, Aprelaâ„¢, is currently undergoing Phase III studies.
Wyeth received an approvable letter for Bazedoxifene in late April 2007. The FDA called for final safety and efficacy data from Phase III studies, and acceptable valuation of manufacturing and testing facilities where problems were found earlier in the year. Wyeth is working with the FDA to resolve these issues, and expects an FDA action date at year end.
CITATIONS
BROWN, EMILY. “Wyeth’s osteoporosis drug cut risk of new fractures”. Retrieved 2007-09-28. “Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis”. Retrieved 2007-09-28.